NLG919
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18949383
| Cas No. |
1402836-58-1 |
|---|---|
| Purity |
≥98% |
| Formula |
C18H22N2O |
| Formula Wt. |
282.39 |
| IUPAC Name |
1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol |
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014 Dec 15;3(10):e957994. PMID: 25941578.
Li M, Bolduc AR, Hoda MN, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. PMID: 25054064.
